Michele Nicolai

Dr. Michele Nicolai

Ospedali Riuniti di Ancona, Ancona, Marche, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Vision
Verified
Journal Article
Open access
PDF file
MNMichele Nicolai
Michele Nicolai
NLNicola Lassandro
Nicola Lassandro
AFAlessandro Franceschi
Alessandro Franceschi
ARAlessandro Rosati
Alessandro Rosati
STSerena De Turris
Serena De Turris
CMCesare Mariotti
Cesare Mariotti
Silicone oil represents the main choice for intraocular tamponade in cases of complicated retinal detachment surgery. The intraocular pressure of an eye filled with silicone oil could increase, driven by a variety of different forces, according to several mechanisms. Two main conditions have been highlighted, depending on the onset: early hypertension or late glaucoma. The different types of silicone oils and their physico-chemical properties are varied and may play a role in the determination of intraocular pressure rise. The current body of literature allows for the illustration and categorization of the incidence and risk factors, as well as the pathogenesis and the management of the early postoperative hypertension subtended by an open- and closed-angle, along with the late onset silicone oil-induced glaucoma. Understanding the leading actors on the stage of ocular pressure elevation concurrently with silicone oil application for retinal surgery could help in guiding the timely and appropriate course of treatment.

15 November 2013 in Eye
Verified
Journal Article
Closed access
CMC Mariotti
C Mariotti
EDE Dahan
E Dahan
MNMichele Nicolai
Michele Nicolai
LLL Levitz
L Levitz
SBS Bouee
S Bouee

1 May 2015 in Retina
Verified
Journal Article
Open access
MRMichele Reibaldi
Michele Reibaldi
ALAntonio Longo
Antonio Longo
TATeresio Avitabile
Teresio Avitabile
VBVincenza Bonfiglio
Vincenza Bonfiglio
Mario Damiano ToroMario Damiano Toro
Mario Damiano Toro
CMCesare Mariotti
Cesare Mariotti
To compare the clinical outcomes and the rate of complications of 27-gauge transconjunctival nonvitrectomizing vitreous surgery (NVS) and of 25-gauge transconjunctival sutureless vitrectomy surgery for idiopathic epiretinal membrane removal. In this prospective randomized study, 83 phakic eyes of 83 consecutive patients with an idiopathic epiretinal membrane were randomized to receive 27-gauge NVS (NVS-group) or 25-gauge vitrectomy (Standard-group). Main outcome measures were best-corrected visual acuity, central retinal thickness, nuclear density units' changes, and rate of complications. Thirty-nine eyes of the Standard-group and 40 of the NVS-group were considered in final analysis. Mean best-corrected visual acuity improved significantly in both groups, with a significant better result at 12 months in NVS-group (P = 0.039; t-test). Central retinal thickness decreased significantly in both groups (P < 0.001, Tukey test), without significant difference between the two groups at any time point. At 12 months, nuclear density increased significantly in the Standard-group (analysis of variance, P < 0.001), and it did not change in the NVS-group (analysis of variance, P = 0.537). Epiretinal membrane recurred in 5.1% of eyes in the Standard-group and in 7.5% of eyes in the NVS-group (Fisher's exact test, P = 1.000). The 27-gauge NVS is an effective surgical procedure in eyes with epiretinal membrane and it induces less progression of nuclear sclerosis than 25-gauge vitrectomy.

16 November 2018 in Aging
Verified
Journal Article
Closed access
RLRaffaella Lazzarini
Raffaella Lazzarini
MNMichele Nicolai
Michele Nicolai
VPVittorio Pirani
Vittorio Pirani
CMCesare Mariotti
Cesare Mariotti
RPRoberto Di Primio
Roberto Di Primio
Regenerative medicine approaches based on mesenchymal stem cells (MSCs) are being investigated to treat several aging-associated diseases, including age-related macular degeneration (AMD). Loss of retinal pigment epithelium (RPE) cells occurs early in AMD, and their transplant has the potential to slow disease progression.The human RPE contains a subpopulation of cells - adult RPE stem cells (RPESCs) - that are capable of self-renewal and of differentiating into RPE cells in vitro. However, age-related MSC changes involve loss of function and acquisition of a senescence-associated secretory phenotype (SASP), which can contribute to the maintenance of a chronic state of low-grade inflammation in tissues and organs.In a previous study we isolated, characterized, and differentiated RPESCs. Here, we induced replicative senescence in RPESCs and tested their acquisition of the senescence phenotype and the SASP as well as the differentiation ability of young and senescent RPESCs.Senescent RPESCs showed a significantly reduced proliferation ability, high senescence-associated β-galactosidase activity, and SASP acquisition. RPE-specific genes were downregulated and p21 and p53 protein expression was upregulated.These findings document the effects of senescence and SASP acquisition on RPESC differentiation ability and highlight the need for a greater understanding of their role in AMD pathogenesis.

1 January 2013 in Clinical Ophthalmology
Verified
Journal Article
Open access
CBClaudia Bruè
Claudia Bruè
ASAndrea Saitta
Andrea Saitta
MNMichele Nicolai
Michele Nicolai
CMCesare Mariotti
Cesare Mariotti
AGAlfonso Giovannini
Alfonso Giovannini
Peer reviewed article authored by (Bruè C, Saitta A, Nicolai M, Mariotti C, Giovannini A). Read article or submit your manuscript for publishing.

6 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMichele Nicolai
Michele Nicolai
AFAlessandro Franceschi
Alessandro Franceschi
STSerena De Turris
Serena De Turris
ARAlessandro Rosati
Alessandro Rosati
VPVittorio Pirani
Vittorio Pirani
CMCesare Mariotti
Cesare Mariotti
Purpose: To investigate papillary microvascular changes in patients affected by macular edema due to Central Retinal Vein Occlusions (CRVO) after anti-Vascular Endothelial Growth Factor (VEGF) therapy. Methods: Prospective analysis of papillary and peripapillary vessel density (VD) changes in 18 eyes of 18 hypertensive patients affected by CRVO before and after the loading-phase of intravitreal Ranibizumab (IVR) injections. Data were quantitatively measured by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) before as well as 1 month and 4 months after injections. The correlation between post-treatment best-corrected visual acuity (BCVA) and changes in the retinal microvasculature evaluated by OCTA was assessed. Results: 18 eyes of 18 consecutive patients with a known history of arterial hypertension and affected by an acute CRVO episode were enrolled. Central macular thickness (CMT) was significantly reduced after IVR injections (p < 0.001), while mean BCVA improved from 0.70 ± 0.26 logarithm of the minimal angle of resolution (logMAR) units at baseline to 0.25 ± 0.18 logMAR units after 4 months (p < 0.001). VD inside disc and peripapillary significantly increased (p < 0.001 and p = 0.01, respectively) after treatment. Conclusions: OCTA showed VD increase in the papillary area in patients affected by CRVO after anti-VEGF therapy. This area could represent a new region of interest to study microvasculature changes concomitant with severe macular edema.